Essential Fatty Acids: A Potential Solution for Post-COVID-19 Long-Haul Manifestations

This blog was written by Undurti N. Das. Prof. Das is a clinical immunologist, endocrinologist and the founder president and chief executive officer of UND Life Sciences.
Like

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

The aftermath of COVID-19 continues to unveil various challenges, with a significant number of individuals experiencing prolonged symptoms even after recovering from the acute phase of the illness. Commonly referred to as "long-haul syndrome," these lingering manifestations encompass a spectrum of issues ranging from fatigue to neurological impairments, posing significant hurdles to recovery [1, 2]. Although several hypotheses have attempted to elucidate the underlying mechanisms, there remains a critical gap in understanding why these symptoms persist and how best to address them [2, 3].

The Role of Essential Fatty Acids (EFAs) in Post-COVID-19 Management

In a recent study by Undurti N. Das published in Lipids in Health and Disease, a compelling hypothesis was proposed regarding the potential role of essential fatty acids (EFAs) in preventing and alleviating post-COVID-19 long-haul manifestations [4]. Das suggested that deficiencies in EFAs and dysregulation of their metabolism may contribute to the development and persistence of symptoms associated with long-haul syndrome [4].

Understanding the Hypothesis

Das's hypothesis stems from the multifaceted roles EFAs play in modulating various physiological processes, particularly those relevant to the immune response and tissue homeostasis [4]. EFAs and their metabolites exhibit immunomodulatory properties, influencing the host's response to viral infections such as SARS-CoV-2 [4]. These compounds have been shown to regulate cytokine release, exert cytoprotective effects, modulate neurotransmitter production, inhibit inflammatory pathways, and promote tissue repair and regeneration [4].

Implications for Post-COVID-19 Recovery

Considering the broad spectrum of actions attributed to EFAs, their administration may hold promise for mitigating the symptoms of long-haul syndrome and promoting recovery in individuals recovering from COVID-19 [4]. By addressing underlying deficiencies and supporting essential physiological processes, EFAs could alleviate fatigue, cognitive impairments, cardiac complications, and other persistent symptoms associated with long-haul syndrome [4].

Conclusion

The hypothesis put forth by Das underscores the importance of exploring novel approaches to address the complex challenges posed by post-COVID-19 long-term manifestations. Although further research is needed to validate these findings and elucidate the mechanisms involved, the potential role of EFAs in post-COVID-19 management offers a glimmer of hope for individuals experiencing persistent symptoms.

References:

Das UN. Can essential fatty acids (EFAs) prevent and ameliorate post-COVID-19 long haul manifestations? Lipids in Health and Disease. 2024; 23: 112.

National Institutes of Health. Post-Acute Sequelae of SARS-CoV-2 infection (PASC) [Internet]. Available from: https://www.nih.gov/research-training/medical-research-initiatives/pasc

Carfì A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020; 324(6): 603–605.

Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021; 27(4): 626-631.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Subscribe to the Topic

COVID19
Life Sciences > Health Sciences > Clinical Medicine > Diseases > Infectious Diseases > COVID19
Diseases
Life Sciences > Health Sciences > Clinical Medicine > Diseases
Health Promotion and Disease Prevention
Life Sciences > Health Sciences > Public Health > Health Promotion and Disease Prevention
Fatty Acids
Life Sciences > Biological Sciences > Chemical Biology > Lipidology > Lipids > Fatty Acids

Related Collections

With collections, you can get published faster and increase your visibility.

Role of lipids and lipid metabolism in cancer

Lipids in Health and Disease invites you to contribute a manuscript to our new thematic series, “Role of lipids and lipid metabolism in cancer”. There is emerging evidence that lipids and lipid metabolism are essential for cancer growth. In hepatocellular carcinoma a decline of apoptotic lipids like ceramides is supposed to hinder death of cancer cells. Accumulation of saturated fats may protect the cells from oxidative stress. Enhanced lipogenesis is essential for cell proliferation. Disturbed lipid metabolism was also described in other cancers. The identification of suitable serum lipid biomarkers as diagnostic tools is in the focus of current research. Lipid metabolism may also become a target for cancer therapy. All submissions should be made by 31st December, 2021. The collection of papers in this Special Issue addresses the role of lipids and lipid metabolism in cancer. We warmly welcome all articles and reviews on solid and non-solid tumors. This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process.

Publishing Model: Open Access

Deadline: Ongoing

Targeting Lipids for Cardiovascular Health: Novel Mechanisms and Therapeutics

People who maintain ideal cardiovascular health have high life expectancy and low lifetime risk of disabling and life-threatening medical conditions. Therefore, the identification and adoption of novel strategies to pursue ideal cardiovascular health represent a vital opportunity to improve the prevention and treatment of cardiovascular diseases. Because atherogenic lipids and lipoproteins play a causal role in the initiation and progression of endothelial dysfunction and atherosclerosis, maintenance of optimal lipid levels is necessary to attain ideal cardiovascular health status. Evidence from Mendelian randomization studies and randomized trials has conclusively demonstrated that lower low-density lipoprotein cholesterol (LDL-C) can effectively reduce cardiovascular risks. Additional benefits may derive from lowering triglycerides and lipoprotein(a) and elevating serum levels and activity of high-density lipoprotein cholesterol (HDL-C). To date, numerous challenges and controversies exist concerning the cumulative effect of lipid-carrying lipoproteins on cardiovascular health, the magnitude of the clinical benefit obtained by achieving and maintaining optimal lipid levels and the best timing to initiate lipid-modifying strategies to mitigate cardiovascular risk.

Publishing Model: Open Access

Deadline: Dec 31, 2023